 
|
Select Links sm
CA 19-9 Received Clearance
by the U.S. FDA for Monitoring
For educational purposes
only; not to be relied upon. Please read Pancreatica Disclaimer
-
-
-
- Links
-
- Fujirebio Diagnostics, Inc.
full press release (in PDF)
-
- Polymedco press release
-
- CA 19-9 product information (in PDF and somewhat technical)
- Quotations
-
- "Recent reports, mainly from Europe,
have shown that serial measurements of serum CA 19-9 can reflect
the response of patients to chemotherapy. The availability of
the CA 19-9 test in the U.S. will give us a new tool for early
assessment of the effectiveness of the many new drugs that are
becoming available for the treatment of metastatic cancer of
the pancreas."
-
- Herbert A. Fritsche, PhD
Chief, Clinical Chemistry, M.D. Anderson Cancer Center
-
-
-
- “CA 19-9 is an extremely useful marker
of disease status, especially when assessed frequently since,
in conjunction with clinical assessment, it enables clinical
decisions with respect to treatment options to be made earlier
to the benefit of the patient. The availability of CA 19-9 in
the US will positively impact the care and management of patients
with pancreatic cancer.”
-
- Jules Harris, MD
Professor, Immunology and Microbiology, Rush Medical College
|
